Quarterly report pursuant to Section 13 or 15(d)

Composition of Certain Financial Statement Captions (Tables)

v3.3.0.814
Composition of Certain Financial Statement Captions (Tables)
9 Months Ended
Sep. 30, 2015
Compositions of Certain Financial Statement Captions [Abstract]  
Composition of certain financial statement captions
(In thousands)
September 30,
2015
 
December 31,
2014
Accounts receivable, net
 
 
 
Accounts receivable
$
198,840

 
$
21,875

Less: allowance for doubtful accounts
(9,115
)
 
(1,906
)
 
$
189,725

 
$
19,969

Inventories, net
 
 
 
Consumable supplies
$
21,119

 
$
279

Finished products
13,851

 
11,837

Work in-process
1,045

 
1,011

Raw materials
5,472

 
4,116

Less: inventory reserve
(794
)
 
(639
)
 
$
40,693

 
$
16,604

Prepaid expenses and other current assets
 
 
 
Deferred tax assets
$
55,527

 
$
1,892

Prepaid supplies
9,298

 
1,123

Other receivables
3,995

 
669

Taxes recoverable
3,083

 
2,417

Other
2,357

 
2,320

Prepaid insurance
594

 
968

 
$
74,854

 
$
9,389

Intangible assets, net:
 
 
 
Customer relationships
$
451,030

 
$
22,108

Technologies
151,791

 
52,508

Trade names
50,431

 
3,483

Licenses
25,399

 
572

Covenants not to compete
8,618

 
8,639

Product registrations
7,642

 
8,763

Other
11,342

 
507

Less:  accumulated amortization
(45,966
)
 
(33,931
)
 
$
660,287

 
$
62,649

Accrued expenses:
 
 
 
Deferred revenue
$
75,763

 
$
4,185

Employee benefits
31,668

 
4,127

Contingent consideration
28,283

 
27,352

Taxes payable
24,024

 
77

Capital leases short-term
10,785

 

Clinical trials
4,351

 
8,643

Professional fees
1,375

 
1,860

Milestone payment
5,000

 

Other
19,864

 
14,668

 
$
201,113

 
$
60,912

 
 
 
 
(In thousands)
September 30,
2015
 
December 31,
2014
Other long-term liabilities:
 
 
 
Deferred revenue
$
178,308

 
$
2,526

Contingent consideration – OPKO Renal
19,210

 
36,529

Contingent consideration – OPKO Health Europe
232

 
254

Contingent consideration – OPKO Diagnostics
7,683

 
6,992

Contingent consideration – CURNA
450

 
440

Mortgages and other debts payable
4,735

 
2,434

Capital leases long-term
7,120

 

Other
18,738

 
1,030

 
$
236,476

 
$
50,205

Schedule of goodwill
The following table reflects the changes in Goodwill during the nine months ended September 30, 2015.
 
2015
(In thousands)
Balance at January 1st
 
Acquisitions and deconsolidation
 
Foreign exchange
 
Balance at September 30th
Pharmaceuticals
 
 
 
 
 
 
 
CURNA
$
4,827

 
$

 
$

 
$
4,827

EirGen

 
66,823

 
273

 
67,096

FineTech
11,698

 

 

 
11,698

OPKO Chile
5,283

 

 
(739
)
 
4,544

OPKO Biologics
139,784

 

 

 
139,784

OPKO Health Europe
8,013

 

 
(600
)
 
7,413

OPKO Mexico
100

 

 
(13
)
 
87

OPKO Renal
2,069

 

 

 
2,069

SciVac
1,553

 
(1,553
)
 

 

 
 
 
 
 
 
 
 
Diagnostics
 
 
 
 
 
 
 
Bio Reference

 
472,751

 

 
472,751

OPKO Diagnostics
17,977

 

 

 
17,977

OPKO Lab
32,988

 

 

 
32,988

 
$
224,292

 
$
538,021

 
$
(1,079
)
 
$
761,234